Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.

Cancer research - 2 Dec 2024

Smith Margaret R, Dixon Caroline B, Wang Yuezhu, Liu Yin, D'Agostino Ralph, Ruiz Jimmy, Oliver George, Miller Lance D, Topaloglu Umit, Chan Michael D, Farris Michael, Su Jing, Mileham Kathryn F, Zhao Dawen, Li Wencheng, Sexton Tammy, Lycan Thomas, Haas Karen M, Grayson Jason M, Xing Fei

Abstract excerpt

Treatment of non-small cell lung cancer (NSCLC) has drastically changed in recent years owing to the robust anticancer effects of immune checkpoint inhibitors (ICI). However, only 20% of the patients with NSCLC benefit from ICIs, highlighting the need to uncover the mechanisms mediating resistance. By analyzing the overall survival (OS) and mutational profiles of 424 patients with NSCLC who received ICI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Indazoles

Share to Lung Neoplasms

Share to Receptor, trkA

Share to Tumor Microenvironment

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39250241
DOI: 10.1158/0008-5472.CAN-24-0658
PMCID: PMC11611666

Genes

NTRK1
C3
CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.PMID 39250241Read ↗

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.Semantic proximity Read ↗

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.Semantic proximity Read ↗

Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.Semantic proximity Read ↗

Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity Read ↗

Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non-Small Cell Lung Cancer: A Nationwide CCAT Cohort From Japan.Semantic proximity Read ↗

UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer.Semantic proximity Read ↗

Efficacy of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR-mutationsSemantic proximity Read ↗

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.Semantic proximity Read ↗

Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.Semantic proximity Read ↗

Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.Semantic proximity Read ↗

Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.